| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michael A Nauc. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes care. vol 36. issue 7. 2014-02-03. PMID:23645884. |
glucagon-like peptide 1 (glp-1) receptor agonists demonstrate an efficacy comparable to insulin treatment and appear to do so with significant effects to promote weight loss with minimal hypoglycemia. |
2014-02-03 |
2023-08-12 |
Not clear |
| Peter C Butler, Michael Elashoff, Robert Elashoff, Edwin A M Gal. A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes care. vol 36. issue 7. 2014-02-03. PMID:23645885. |
glucagon-like peptide 1 (glp-1) receptor agonists demonstrate an efficacy comparable to insulin treatment and appear to do so with significant effects to promote weight loss with minimal hypoglycemia. |
2014-02-03 |
2023-08-12 |
Not clear |
| Young-Sun Lee, Hee-Sook Ju. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism: clinical and experimental. vol 63. issue 1. 2014-02-03. PMID:24140094. |
glp-1 lowers blood glucose levels by stimulating insulin secretion from pancreatic beta-cells in a glucose-dependent manner. |
2014-02-03 |
2023-08-12 |
Not clear |
| Young-Sun Lee, Hee-Sook Ju. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism: clinical and experimental. vol 63. issue 1. 2014-02-03. PMID:24140094. |
this review outlines our knowledge of the actions of glp-1 on insulin secretion and biosynthesis, beta-cell proliferation and regeneration, and protection against beta-cell damage, as well as the involvement of recently discovered signaling pathways of glp-1 action, mainly focusing on pancreatic beta-cells. |
2014-02-03 |
2023-08-12 |
Not clear |
| Ji-sheng Wan. [Research progress of mechanisms through which dipeptidyl peptidase-4 inhibitors regulate glycemia]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae. vol 35. issue 2. 2014-01-30. PMID:23643015. |
in recent years, studies have revealed many possible mechanisms through which dpp-4 inhibitors regulate glycemia: dpp-4 inhibitors may selectively reduce dpp-4 activity in the intestine, causing the increase of portal plasma glp-1 level and thus promoting the release of insulin via nerve reflex;also, they may decrease the cleavage product of glp-1 and reduce the degradation of other bioactive peptides. |
2014-01-30 |
2023-08-12 |
Not clear |
| Josephine M Forbes, Samantha P Cowan, Sofianos Andrikopoulos, Amy L Morley, Leigh C Ward, Karen Z Walker, Mark E Cooper, Melinda T Coughla. Glucose homeostasis can be differentially modulated by varying individual components of a western diet. The Journal of nutritional biochemistry. vol 24. issue 7. 2014-01-29. PMID:23313044. |
when compared to the control and high age diets, excess consumption of the diet high in saturated fat (animal source) increased body weight and adiposity, and decreased insulin sensitivity, as defined by homa ir, impaired skeletal muscle insulin signaling and insulin hypersecretion in the context of increased circulating glucagon-like peptide (glp-1). |
2014-01-29 |
2023-08-12 |
rat |
| S H Locki. Glucagon-like peptide-1 receptor in the brain: role in neuroendocrine control of energy metabolism and treatment target for obesity. Journal of neuroendocrinology. vol 25. issue 7. 2014-01-28. PMID:23590331. |
glp-1 receptor agonism promotes insulin release and is currently used to treat type 2 diabetes humans, with a common side effect being weight loss. |
2014-01-28 |
2023-08-12 |
Not clear |
| Niels-Erik Viby, Marie S Isidor, Katrine B Buggeskov, Steen S Poulsen, Jacob B Hansen, Hannelouise Kisso. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. vol 154. issue 12. 2014-01-28. PMID:24092637. |
the incretin hormone glucagon-like peptide-1 (glp-1) is an important insulin secretagogue and glp-1 analogs are used for the treatment of type 2 diabetes. |
2014-01-28 |
2023-08-12 |
mouse |
| Pitchai Balakumar, Sokkalingam A Dhanara. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. Cellular signalling. vol 25. issue 9. 2014-01-27. PMID:23707531. |
the incretin hormones such as glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are released from the small intestine into the vasculature during a meal, and these incretins have a potential to release insulin from pancreatic beta cells of islets of langerhans, affording a glucose-lowering action. |
2014-01-27 |
2023-08-12 |
human |
| Abby S Klosterbuer, William Thomas, Joanne L Slavi. Resistant starch and pullulan reduce postprandial glucose, insulin, and GLP-1, but have no effect on satiety in healthy humans. Journal of agricultural and food chemistry. vol 60. issue 48. 2014-01-24. PMID:23136915. |
resistant starch and pullulan reduce postprandial glucose, insulin, and glp-1, but have no effect on satiety in healthy humans. |
2014-01-24 |
2023-08-12 |
human |
| Abby S Klosterbuer, William Thomas, Joanne L Slavi. Resistant starch and pullulan reduce postprandial glucose, insulin, and GLP-1, but have no effect on satiety in healthy humans. Journal of agricultural and food chemistry. vol 60. issue 48. 2014-01-24. PMID:23136915. |
visual analog scales assessed appetite, and blood samples were collected to measure glucose, insulin, ghrelin, and glucagon-like peptide-1 (glp-1). |
2014-01-24 |
2023-08-12 |
human |
| Abby S Klosterbuer, William Thomas, Joanne L Slavi. Resistant starch and pullulan reduce postprandial glucose, insulin, and GLP-1, but have no effect on satiety in healthy humans. Journal of agricultural and food chemistry. vol 60. issue 48. 2014-01-24. PMID:23136915. |
rs+p significantly reduced glucose, insulin, and glp-1, but neither scf treatment differed from control. |
2014-01-24 |
2023-08-12 |
human |
| Caroline L Bodinham, Najlaa M Al-Mana, Leanne Smith, M Denise Robertso. Endogenous plasma glucagon-like peptide-1 following acute dietary fibre consumption. The British journal of nutrition. vol 110. issue 8. 2014-01-22. PMID:23507477. |
changes to glp-1, glucose, insulin and c-peptide were assessed half hourly for 7 h. following the breakfast meal, plasma glp-1 concentrations were lower with ham-rs2 compared with the placebo (p = 0·025). |
2014-01-22 |
2023-08-12 |
human |
| S Mudalia. Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes. International journal of clinical practice. vol 67. issue 9. 2014-01-21. PMID:23952467. |
data from prospective studies and clinical trials suggest that lifestyle modifications and certain antihyperglycaemic medications, including thiazolidinediones (tzds), glucagon-like peptide-1 (glp-1) agonists, dipeptidyl peptidase-4 (dpp-4) inhibitors and insulin, may preserve or enhance β-cell function. |
2014-01-21 |
2023-08-12 |
Not clear |
| Dong Yang, Yukako Nakajo, Koji Iihara, Hiroharu Kataoka, Hiroji Yanamot. Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain research. vol 1517. 2014-01-17. PMID:23602966. |
glucagon-like peptide-1 (glp-1), an enhancer of insulin production with a trophic effect on β cells in the islets, has been found to be trophic for neuronal cells. |
2014-01-17 |
2023-08-12 |
mouse |
| Asieh Mansour, Saeed Hosseini, Bagher Larijani, Mohamad Pajouhi, Mohammad Reza Mohajeri-Tehran. Nutrients related to GLP1 secretory responses. Nutrition (Burbank, Los Angeles County, Calif.). vol 29. issue 6. 2014-01-16. PMID:23415393. |
the activities of glp-1 include stimulating insulin gene expression and biosynthesis, improving β-cell proliferation, exogenesis, and survival. |
2014-01-16 |
2023-08-12 |
Not clear |
| Asieh Mansour, Saeed Hosseini, Bagher Larijani, Mohamad Pajouhi, Mohammad Reza Mohajeri-Tehran. Nutrients related to GLP1 secretory responses. Nutrition (Burbank, Los Angeles County, Calif.). vol 29. issue 6. 2014-01-16. PMID:23415393. |
the pleiotropic actions of glp-1, especially its glucose-lowering effect, gave rise to the suggestion that it is a novel approach to insulin resistance treatment. |
2014-01-16 |
2023-08-12 |
Not clear |
| Asieh Mansour, Saeed Hosseini, Bagher Larijani, Mohamad Pajouhi, Mohammad Reza Mohajeri-Tehran. Nutrients related to GLP1 secretory responses. Nutrition (Burbank, Los Angeles County, Calif.). vol 29. issue 6. 2014-01-16. PMID:23415393. |
hormones secreted from the gut including glp-1, which are involved in the regulation of insulin sensitivity and secretions, have been found to be affected by nutrient intake. |
2014-01-16 |
2023-08-12 |
Not clear |
| Bodo C Melnik, Swen Malte John, Gerd Schmit. Milk is not just food but most likely a genetic transfection system activating mTORC1 signaling for postnatal growth. Nutrition journal. vol 12. 2014-01-16. PMID:23883112. |
this review presents milk as a materno-neonatal relay system functioning by transfer of preferential amino acids, which increase plasma levels of glucose-dependent insulinotropic polypeptide (gip), glucagon-like peptide-1 (glp-1), insulin, growth hormone (gh) and insulin-like growth factor-1 (igf-1) for mtorc1 activation. |
2014-01-16 |
2023-08-12 |
human |
| R E van Genugten, D L Möller-Goede, D H van Raalte, M Diaman. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. Diabetes, obesity & metabolism. vol 15. issue 7. 2014-01-10. PMID:23216746. |
beside its effect on pancreatic insulin secretion, glp-1 exerts several extra-pancreatic effects such as slowing down gastric emptying, promoting satiety and reducing food intake and weight loss. |
2014-01-10 |
2023-08-12 |
Not clear |